Definitive Contract 75N91019C00012
Award Date
9/16/19
Potential Completion Date
3/15/21
Potential Value
$300K
Federal Agency
National Cancer Institute
Awardee
Cellsight Technologies, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Francisco, CA 94107, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
95
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $247,568 Firm Fixed Price contract awarded by the National Cancer Institute (NCI) to Cellsight Technologies, Inc., a woman-owned small business. The contract is for research and development related to a novel PET imaging agent, [18F]F-ARAG, to assess response to cancer immunotherapies. This contract is part of NCI's Small Business Innovation Research (SBIR) program, which sets aside certain research and development contracts for small businesses. Cellsight Technologies has also...
This is a $1,995,174 Firm Fixed Price (FFP) Definitive Contract awarded by the National Cancer Institute (NCI) to Cellsight Technologies, Inc., a woman-owned small business. The contract is for SBIR Phase II research and development of the [18F]F-ARAG imaging agent to assess response to cancer immunotherapies in non-small cell lung cancer. This builds on a previous $300,000 SBIR Phase I contract from NCI to evaluate [18F]F-ARAG for predicting response to cancer immunotherapies. The contract...
This is a $299,640.99 Firm Fixed Price contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Cellsight Technologies, Inc. The contract is for research and development services related to a noninvasive PET imaging strategy for longitudinal monitoring of the tumor microenvironment, under the Small Business Innovation Research (SBIR) program. The contract was set aside for small business participation. Cellsight Technologies, Inc....
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Radiopharmaceutical Imaging and Dosimetry, LLC, doing business as Radiopharmaceutical Imaging & Dosimetry LLC, a small business. The contract, valued at $299,275, is for a Small Business Innovation Research (SBIR) Phase I project to optimize targeted radionuclide therapy for metastatic liver cancer patients. This contract supports the NCI's broader...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Sibtech, Inc., a for-profit manufacturer, for the development of a positron emission tomography (PET) tracer to image the programmed death-ligand 1 (PD-L1) protein. The contract has a firm-fixed price of $349,735.00 and a completion date of April 17, 2021. The contract opportunity was initially posted on June 29, 2017, with...
This is a $189,094.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Angiocrine Bioscience, Inc., a for-profit organization. The contract is for the "SBIR PHASE I LARGE SCALE PROPAGATION OF CANCER CELLS USING THE VERAVEC PLATFORM IN AN AUTOMATED CLOSED SYSTEM" and was set aside for small businesses. The contract has an ultimate completion date of July 21, 2016 and was awarded on September 22, 2015. This appears to be a Small Business...
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Neuralrad LLC, a small business, for $454,559.00. The contract was awarded under the SBIR (Small Business Innovation Research) program to support the development of "Quantitative Imaging Software Tools for Cancer Diagnosis and Treatment Planning" as described in the original solicitation. This Phase I SBIR contract has a period of performance from...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...
This is a $300,000.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Icagen, Inc. for a Small Business Innovation Research (SBIR) Phase I project titled "SYSTEMIC TARGETED RADIONUCLIDE THERAPY FOR CANCER TREATMENT". The period of performance is from September 22, 2015 to June 21, 2016, with an ultimate completion date of September 30, 2016. This contract was not set aside for a specific business size or type. The goal of this SBIR...